Guardant Health shares are trading higher after the company launched the new Guardant360 TissueNext test. Additionally, Canaccord Genuity maintained a Buy rating while raising its price target to $38.
Portfolio Pulse from Benzinga Newsdesk
Guardant Health shares are trading higher following the launch of the new Guardant360 TissueNext test. Canaccord Genuity has maintained a Buy rating and raised its price target to $38.
June 05, 2024 | 3:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guardant Health shares are trading higher after the launch of the new Guardant360 TissueNext test. Canaccord Genuity has maintained a Buy rating and raised its price target to $38.
The launch of a new product, Guardant360 TissueNext test, is likely to drive investor optimism and increase demand for the stock. Additionally, the positive analyst rating and increased price target from Canaccord Genuity further support a bullish outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100